Riskpilot← Back to searchSign inGet full accessNAVAMEDIC ASA
ASAActiveOrg 985012059Henrik Ibsens Gate 100, 0255 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 200222 employeeswww.navamedic.com
Revenue 2024
NOK 52,8M
+11% vs 2023
EBITDA margin
-26.4%
+52% vs 2023
Equity ratio
34.6%
Financial strength
Net profit 2024
NOK -16,7M
+17% vs 2023
| Revenue | NOK 52,8M | +11% |
| EBITDA | NOK -13,9M | +52% |
| Net profit | NOK -16,7M | +17% |
| Total assets | NOK 512,3M | -7% |
| Equity | NOK 177,2M | -12% |
| Employees | 22 | — |
Legal name
NAVAMEDIC ASA
Org number
985012059
Legal form
Allmennaksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. november 2002
Share capital
NOK 17 746 219
Employees
22 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikle, produsere, markedsføre og selge legemidler og relaterte produkter, utføre konsulenttjenester i denne sammenheng, samt å investere i relatert virksomhet.
Address
Henrik Ibsens Gate 100, 0255 Oslo
Phone
+4767112540
Email
infono@navamedic.com
Website
www.navamedic.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 30 788 | 45 261 | 46 250 | 47 632 | 52 803 |
| Staff expenses | −18 891 | −0 | −30 523 | −36 830 | −40 171 |
| EBITDA | −8 185 | −3 344 | −5 580 | −29 310 | −13 928 |
| Depreciation & amort. | −637 | −3 428 | −4 156 | −4 351 | −3 826 |
| EBIT | −8 822 | −6 772 | −9 735 | −33 661 | −17 754 |
| Net financials | −8 461 | 3 489 | 59 040 | 13 555 | 1 088 |
| Profit before tax | −17 283 | −3 283 | 49 305 | −20 106 | −16 666 |
| Tax | −0 | −0 | 8 333 | −94 | −4 |
| Net profit | −17 283 | −3 283 | 40 972 | −20 012 | −16 662 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 218 624 | 216 641 | 297 700 | 552 653 | 512 328 |
| Equity | 128 226 | 145 728 | 212 769 | 201 622 | 177 213 |
| Long-term debt | 65 413 | 44 194 | 64 664 | 144 705 | 179 156 |
| Short-term debt | 24 985 | 26 719 | 16 506 | 202 338 | 151 732 |
| Total debt | 90 399 | 70 913 | 81 169 | 347 043 | 330 888 |
EBITDA margin
-26.4%
This company
15.8%
Market median
-267% vs market
20202024
Equity ratio
34.6%
This company
38.2%
Market median
+9% vs market
20202024
Return on equity
-9.4%
This company
18.4%
Market median
-151% vs market
20202024
Net profit margin
-31.6%
This company
8.1%
Market median
-490% vs market
20202024
Asset turnover
0.10×
This company
1.12×
Market median
-91% vs market
20202024
Debt / equity
1.89×
This company
0.62×
Market median
-205% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KE Chief Executive Officer | Chief Executive Officer | 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Chairman | 2026 | |
| Board of Directors | 2023 | |
| Board of Directors | 2022 | |
| Board of Directors | 2026 | |
| Former (6) | ||
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Board of Directors | 2022 – 2025 | |
CL | Board of Directors | 2021 – 2021 |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 20.53% | 20.53% | 2023 | |
J.P. Morgan Se | Company | 14.37% | 14.37% | 2024 |
| Individual | 14.35% | 14.35% | 2022 | |
| Company | 12.52% | 12.52% | 2024 | |
Ubs Switzerland Ag | Company | 11.17% | 11.17% | 2024 |
| Individual | 8.45% | 8.45% | 2022 | |
| Company | 5.17% | 5.17% | 2024 | |
| Individual | 5.02% | 5.02% | 2022 | |
Skandinaviska Enskilda Banken Ab | Company | 4.71% | 4.71% | 2024 |
| Company | 4.37% | 4.37% | 2024 | |
| Individual | 3.45% | 3.45% | 2022 | |
| Company | 3.4% | 3.4% | 2024 | |
| Individual | 3.3% | 3.3% | 2022 | |
| Company | 3.2% | 3.2% | 2024 | |
| Company | 2.83% | 2.83% | 2024 | |
| Company | 2.83% | 2.83% | 2024 | |
| Individual | 2.72% | 2.72% | 2022 | |
Caceis Bank | Company | 2.3% | 2.3% | 2024 |
| Company | 2.02% | 2.02% | 2024 | |
| Individual | 2.01% | 2.01% | 2024 | |
| Individual | 1.55% | 1.55% | 2022 | |
| Company | 1.46% | 1.46% | 2022 | |
| Company | 1.42% | 1.42% | 2024 | |
| Company | 1.33% | 1.33% | 2023 | |
| Individual | 1.25% | 1.25% | 2022 | |
| Individual | 1.24% | 1.24% | 2024 | |
Kraeber Verwaltung Gmbh | Company | 1.22% | 1.22% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NAVAMEDIC ASA 
Observe Medical AsaBoard members of NAVAMEDIC ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kathrine Elisabeth Gamborg Andreassen | Chief Executive Officer | 0 companies |
| Rune Wahl | Board of Directors | 0 companies |
| Kjell Erik Nordby | Board of Directors | 0 companies |
| Inger Johanne Solhaug | Board of Directors | 0 companies |
| Jostein Asbjørn Davidsen | Chairman | 0 companies |
| Narve Reiten | Board of Directors | 0 companies |
| Morten Jurs | Chairman | 0 companies |
| Terje Bakken | Chairman | 0 companies |
| Annika Maria Kollen | Board of Directors | 0 companies |
| Cheng Lu | Board of Directors | 0 companies |
| Åsa Margaretha Kornfeld | Board of Directors | 0 companies |
| Edmée Jeanne Steenken | Board of Directors | 0 companies |
| Mads Helmich Pedersen | Board of Directors | 0 companies |